The case for & against
Bull & Bear analysis
Bullish
Inhibrx Biosciences, Inc. (NASDAQ: INBX) is an emerging biotechnology company specializing in the development of novel therapeutics targeting difficult-to-treat cancers and autoimmune diseases. The firm is distinctive in its approach to harnessing the power of the immune system through its product pipeline, primarily focusing on OX40 agonists. With its innovative research and significant clinical trial advancements, Inhibrx is positioned at the forefront of immunotherapy within the biotech sector, particularly in oncology.
Bull says
- ↑Phase 2 HexAgon trial shows cORR 48.3% vs 26.5% and median PFS of 9.6 mo
- ↑CEO Mark Lappe net-bought 25 k shares at $99–112, indicating undervaluation belief
- ↑BlackRock invested $78.3 M and Corient $2.7 M, boosting institutional support
- ↑Consensus analyst PT of $197.50 implies ~100% upside from current levels
- ↑Large HNSCC patient pool and expedited regulatory paths offer significant market opportunity
- ↑Potential share buybacks could enhance value as price stabilizes
Bear says
- ↓Q3 EPS loss of $2.34 vs estimates underscores high burn rate
- ↓Shares plunged 11.1% to $97.06 post-trial, signaling persistent market skepticism
- ↓Moderate Buy ratings and mixed analyst views cloud outlook
- ↓Regulatory uncertainty may delay INBRX-106 approval and revenue ramp
- ↓High operating costs and cash burn pressure the company’s runway
- ↓Elevated volatility and rich valuations raise downside risk